Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Mol Cell Endocrinol (2009) 297:13740
Understanding that semaglutide must be injected subcutaneouslynot intramuscularly or intradermallyis fundamental to achieving optimal therapeutic outcomes and minimizing adverse effects
Key points: In the only head-to-head trial, Wegovy produced 15.8% weight loss compared with 6.4% for Saxenda over the same 68-week period Wegovy 7.2 mg (approved January 2026) produces even greater results at 20.7% average weight loss Real-world data from Second Nature shows 19.1% weight loss with semaglutide when combined with behavioural support Semaglutide participants were nearly three times more likely to achieve at least 10% weight loss than liraglutide participants Side effects and tolerability Both medications share a similar side-effect profile, predominantly affecting the gastrointestinal tract
Use is restricted to trained professionals operating in laboratory or research settings, following appropriate safety and handling protocols.
Obesity Rev
If side effects are a concern, understanding what to expect helps you manage them
US$ 26.24
US$ 27.86
US$ 25.89
US$ 24.40
